QS Investors LLC raised its stake in Catalent Inc (NYSE:CTLT) by 67.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 117,335 shares of the company’s stock after acquiring an additional 47,366 shares during the quarter. QS Investors LLC owned approximately 0.09% of Catalent worth $4,820,000 as of its most recent SEC filing.
Several other hedge funds also recently bought and sold shares of the company. ArrowMark Colorado Holdings LLC raised its holdings in Catalent by 8.5% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 771,796 shares of the company’s stock valued at $31,705,000 after buying an additional 60,273 shares during the last quarter. AMP Capital Investors Ltd bought a new position in Catalent in the 4th quarter valued at approximately $2,605,000. Alliancebernstein L.P. raised its holdings in Catalent by 10.4% in the 4th quarter. Alliancebernstein L.P. now owns 297,174 shares of the company’s stock valued at $12,208,000 after buying an additional 28,090 shares during the last quarter. WINTON GROUP Ltd raised its holdings in Catalent by 75.6% in the 4th quarter. WINTON GROUP Ltd now owns 93,166 shares of the company’s stock valued at $3,827,000 after buying an additional 40,115 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Catalent by 6.0% in the 4th quarter. Geode Capital Management LLC now owns 1,143,324 shares of the company’s stock valued at $46,967,000 after buying an additional 64,532 shares during the last quarter. 99.89% of the stock is owned by hedge funds and other institutional investors.
CTLT has been the subject of a number of research reports. Zacks Investment Research lowered shares of Catalent from a “buy” rating to a “hold” rating in a report on Friday, March 9th. ValuEngine lowered shares of Catalent from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Royal Bank of Canada started coverage on shares of Catalent in a research report on Wednesday, December 13th. They set an “outperform” rating and a $46.00 target price for the company. First Analysis started coverage on shares of Catalent in a research report on Friday, January 5th. They set an “equal weight” rating for the company. Finally, Bank of America increased their target price on shares of Catalent from $47.00 to $49.00 and gave the company a “buy” rating in a research report on Tuesday, February 6th. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $45.40.
In other news, SVP William Downie sold 9,082 shares of the firm’s stock in a transaction that occurred on Thursday, March 8th. The shares were sold at an average price of $41.80, for a total transaction of $379,627.60. Following the completion of the sale, the senior vice president now owns 46,986 shares of the company’s stock, valued at approximately $1,964,014.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.70% of the company’s stock.
Shares of Catalent Inc (CTLT) opened at $42.19 on Friday. The firm has a market cap of $5,674.04, a P/E ratio of 26.60, a price-to-earnings-growth ratio of 2.44 and a beta of 1.54. The company has a current ratio of 2.22, a quick ratio of 1.78 and a debt-to-equity ratio of 2.66. Catalent Inc has a 52-week low of $27.48 and a 52-week high of $47.87.
Catalent (NYSE:CTLT) last released its earnings results on Monday, February 5th. The company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. The business had revenue of $606.30 million during the quarter, compared to the consensus estimate of $565.05 million. Catalent had a net margin of 3.03% and a return on equity of 23.85%. The company’s revenue for the quarter was up 25.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.27 EPS. equities research analysts forecast that Catalent Inc will post 1.53 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/03/16/qs-investors-llc-boosts-stake-in-catalent-inc-ctlt.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.